Literature DB >> 20444433

NADPH oxidases in cardiovascular disease.

Ralf P Brandes1, Norbert Weissmann, Katrin Schröder.   

Abstract

Reactive oxygen species (ROS) contribute to several aspects of vascular diseases including ischemia-reperfusion injury, scavenging of nitric oxide, or stimulation of inflammation and hypertrophy. NADPH oxidases of the Nox family are differentially expressed in the cardiovascular system, induced or activated by cardiovascular risk factors and importantly contribute to the oxidative burden of vascular diseases. Moreover, NADPH oxidase-derived ROS are important signaling molecules under physiological conditions. In this article, the current knowledge on NADPH oxidase expression, activation, and signaling in the cardiovascular system as well as the impact of risk factors on the function of these proteins will be reviewed. Finally, the contribution of NADPH oxidases to the predominant cardiovascular diseases will be discussed. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20444433     DOI： 10.1016/j.freeradbiomed.2010.04.030

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN： 0891-5849            Impact factor:   7.376


  101 in total

1.  Serum NOX2 as a new biomarker candidate for HBV-related disorders.

Authors:  Yuan Xiong; Yuanyuan Ye; Pu Li; Yahui Xiong; Jinju Mao; Yong Huang; Weixian Chen; Bo Wang
Journal:  Am J Transl Res       Date:  2018-08-15       Impact factor: 4.060

2.  Activation of NADPH oxidase 1 increases intracellular calcium and migration of smooth muscle cells.

Authors:  Matthew C Zimmerman; Maysam Takapoo; Dammanahalli K Jagadeesha; Bojana Stanic; Botond Banfi; Ramesh C Bhalla; Francis J Miller
Journal:  Hypertension       Date:  2011-08-01       Impact factor: 10.190

Review 3.  Therapeutic potential of NADPH oxidase 1/4 inhibitors.

Authors:  G Teixeira; C Szyndralewiez; S Molango; S Carnesecchi; F Heitz; P Wiesel; J M Wood
Journal:  Br J Pharmacol       Date:  2016-07-14       Impact factor: 8.739

Review 4.  Obesity and risk of vascular disease: importance of endothelium-dependent vasoconstriction.

Authors:  Matthias Barton; Oliver Baretella; Matthias R Meyer
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

Review 5.  P21-activated kinase in inflammatory and cardiovascular disease.

Authors:  Domenico M Taglieri; Masuko Ushio-Fukai; Michelle M Monasky
Journal:  Cell Signal       Date:  2014-05-02       Impact factor: 4.315

6.  NADPH oxidase 4 is not involved in hypoxia-induced pulmonary hypertension.

Authors:  C Veith; S Kraut; J Wilhelm; N Sommer; K Quanz; W Seeger; R P Brandes; N Weissmann; K Schröder
Journal:  Pulm Circ       Date:  2016-09       Impact factor: 3.017

7.  Nox-derived ROS are acutely activated in pressure overload pulmonary hypertension: indications for a seminal role for mitochondrial Nox4.

Authors:  Giovanna Frazziano; Imad Al Ghouleh; Jeff Baust; Sruti Shiva; Hunter C Champion; Patrick J Pagano
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-11-08       Impact factor: 4.733

Review 8.  Nox4 and diabetic nephropathy: with a friend like this, who needs enemies?

Authors:  Yves Gorin; Karen Block
Journal:  Free Radic Biol Med       Date:  2013-03-23       Impact factor: 7.376

9.  Chasing cysteine oxidative modifications: proteomic tools for characterizing cysteine redox status.

Authors:  Christopher I Murray; Jennifer E Van Eyk
Journal:  Circ Cardiovasc Genet       Date:  2012-10-01

10.  A novel nontoxic inhibitor of the activation of NADPH oxidase reduces reactive oxygen species production in mouse lung.

Authors:  Intae Lee; Chandra Dodia; Shampa Chatterjee; John Zagorski; Clementina Mesaros; Ian A Blair; Sheldon I Feinstein; Mahendra Jain; Aron B Fisher
Journal:  J Pharmacol Exp Ther       Date:  2013-03-08       Impact factor: 4.030
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.